Who we are

Pulmocide is a unique biopharmaceutical company with a mission to treat common acute and chronic respiratory tract infections associated with serious complications and devastating effects on patients’ quality of life.

Unlike currently available treatments for fungal and viral infections in the lung, our innovative approach to drug development provides targeted delivery to the lung so that infections can be treated with minimal unwanted systemic effects.

The Pulmocide team has an extensive track record in the discovery and development of novel inhaled medicines for respiratory indications. The team has particular expertise in the identification of compounds with optimal characteristics for lung delivery.

  • "On the back of our previous success in the inhaled therapeutic area, we set out with the goal of creating novel therapies for life-threatening lung infections."

    Dr Garth Rapeport
  • “The products that we are developing have the potential to make significant improvements in the standard of care for patients, effectively transforming chronic and crippling conditions in vulnerable populations, into treatable and manageable diseases.”

    Pete Strong
Novel inhaled respiratory medicine development pipeline.

We are developing novel, potent first-in-class anti-infective agents for delivery by inhaled administration for life-threatening lower respiratory infections.


Management Team

  • Dr Garth Rapeport
  • Dr Pete Strong
  • Dr Alison Murray
  • Dr Kaz Ito
  • Dr Lindsey Cass
  • Dr Amanda Davis